Pharmacokinetics (PKs) and safety results from phase II/III trials suggest that, if high trastuzumab serum concentrations are reached early during treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, patients will gain clinical benefit, and the synergistic effects of trastuzumab and chemotherapy will be maximized. This phase I/II study evaluated the PKs, efficacy, and safety of a novel, intensive loading regimen of trastuzumab in women with HER2-positive metastatic breast cancer (MBC).
INTRODUCTION
Trastuzumab (Herceptin; F. Hoffmann-La Roche, Basel, Switzerland) is a humanized monoclonal antibody that specifically targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2). 1 Overexpression of HER2 occurs in 18% to 20% of newly diagnosed breast cancers and is associated with poor prognosis and a more aggressive tumor phenotype. 2, 3 Trastuzumab is the standard of care for HER2-positive metastatic breast cancer (MBC) as first-line therapy in combination with chemotherapy, or in combination with an aromatase inhibitor in postmenopausal patients with a hormone receptor-positive tumor, or as monotherapy for third-line treatment. 4 The pharmacokinetic parameters of trastuzumab originally were determined in phase I to phase IV studies by using single and multiple weekly dosing. [5] [6] [7] [8] In early clinical trials, a weekly dose achieved mean serum trough concentrations (ie, minimum concentrations [C mins ]) of greater than 10 g/mL.
5, 7 The elimination halflife of trastuzumab after the weekly regimen was initially estimated to be 8.3 days, 5 but a nonlinear, mixed-effect pharmacokinetic model that was based on data from phase I to phase III studies later estimated the half-life as 28.5 days (95% CI, 25.5 to 32.8 days). 9 With the current weekly and every-3-weeks trastuzumab regimens that use a loading dose (4 mg/kg or 8 mg/kg, respectively, followed by a 2 mg/kg or 6 mg/kg maintenance dose, respectively) for HER2-positive breast cancer, steady-state serum concentrations are reached by approximately 20 weeks (95% CI, 18 to 24 weeks). 10 If tumors do not respond to trastuzumab, patients often will withdraw from treatment early on, when serum levels are still low.
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There are two possible mechanisms for the clearance of trastuzumab: saturable receptor-mediated or proteolytic cleavage mechanisms. If serum levels are not high enough to saturate receptor-mediated clearance, it is theoretically possible that an individual patient will never achieve steady-state and, therefore, may have a poorer prognosis. It can be hypothesized that a regimen providing a serum concentration of trastuzumab at least equivalent to the established steady-state early in treatment may provide significant clinical benefit by reducing the tumor size and maximizing the synergistic effects of trastuzumab combined with chemotherapy.
A novel, intensive loading schedule of trastuzumab was designed from pharmacokinetic simulation by using population pharmacokinetic parameters derived from a pooled, phase I/II data set. 12 The aim was to obtain a serum concentration of trastuzumab at least equivalent to the established steady-state but to obtain this earlier in treatment. The intensive loading regimen comprised a loading dose of 6 mg/kg intravenous trastuzumab monotherapy given weekly for 3 weeks followed by a maintenance dose of 6 mg/kg every 3 weeks until disease progression occurred. An interim safety analysis of six patients who completed four cycles of study treatment showed promising results.
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This article discusses results from the assessment of this novel, intensive loading regimen in a larger patient cohort.
PATIENTS AND METHODS

Patients
Women age 18 years or older with histologically or cytologically proven HER2-positive MBC (ie, one or more metastatic lesion), centrally confirmed by immunohistochemistry (3ϩ) or fluorescent in situ hybridization (FISH; HER2:CEP17 Ն 2), were enrolled on the study. Samples identified as immunohistochemistry 2ϩ were retested with FISH to determine HER2 status. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 and a left ventricular ejection fraction (LVEF) of Ն 50% at baseline, detected by either multiple-gated acquisition (MUGA) scan or echocardiography. All eligible patients must have recovered from any surgical procedure, radiotherapy, or chemotherapy and have had a lapse of Ն 3 weeks. Informed consent was obtained before any screening procedures were performed. Patients were excluded if they had experienced inadequate renal and liver functions, uncontrolled CNS metastases, invasive malignancy other than breast cancer, dyspnea at rest because of complications of advanced malignancy, or any disease that required supplementary oxygen therapy. Patients with New York Heart Association (NYHA) class II to IV congestive heart failure (CHF) or a history of CHF, myocardial infarction, poorly controlled hypertension, or angina pectoris; clinically significant valvular heart disease; high-risk, uncontrolled arrhythmia; or serious uncontrolled infections also were excluded. Prior anti-HER2 therapy and treatment with any investigational drug within 30 days before the beginning of study medication were not permitted.
The study was performed according to precepts established by the Helsinki Declaration. The protocol was approved by an independent ethics committee affiliated with each study center, and each patient gave written, informed consent to participate.
Study Design
In this single-arm, open-label, multicenter study, all eligible patients received a loading dose of 6 mg/kg intravenous trastuzumab monotherapy over 90 minutes on days 1, 8, and 15 of cycle 1 followed by a maintenance dose of 6 mg/kg every 3 weeks from day 1 of cycle 2. Study treatment continued until disease progression, initiation of an alternative anticancer therapy, unacceptable toxicity, or patient withdrawal occurred. Follow-up was performed until either resolution of adverse events (AEs) occurred or until 24 weeks after study treatment was stopped.
End Points and Assessments
The pharmacokinetics, safety, and tolerability of the intensive loading regimen of trastuzumab monotherapy were the primary end points. Secondary end points were to determine serum concentrations, response rate (RR), and time to progression (TTP).
Pharmacokinetic blood samples were collected before the start of study medication; at the end of infusion; and 1.5 hours after infusions on days 1, 8, and 15 of cycles 1 and 2, on day 1 of cycle 3, and on days 1, 4.5, 5, 8, 11, 15, and 22 (before cycle 5) of cycle 4. Trastuzumab serum concentrations were determined by a validated enzyme-linked immunosorbent assay (Genentech, South San Francisco, CA). Population pharmacokinetic analysis was conducted with the nonlinear mixed-effect modeling program, NONMEM (version VI, Level 1.0; ICON Development Solutions, Dublin, Ireland). Individual post hoc parameters were obtained from this model and were used to estimate the peaks (ie, maximum concentration), troughs (C mins ), and area under the concentration-time curve.
Safety assessments were performed during every clinic visit before trastuzumab administration. AEs were graded according to the National Cancer Institute Common Toxicity Criteria version 2.0, and CHF was graded according to NYHA classification. ECGs were performed at screening and as clinically indicated. LVEF was evaluated every 12 weeks by either echocardiography or MUGA scan (whichever method was used before starting study medication). For patients with an LVEF less than 40% or with an LVEF less than 45% and greater than 10 percentage points (pp) less than baseline, trastuzumab was held temporarily, and LVEF evaluation was repeated after 3 weeks. Patients who still met these LVEF criteria after 3 weeks discontinued trastuzumab permanently.
For patients with measurable disease, RR was determined by using Response Evaluation Criteria In Solid Tumors, 14 and TTP was evaluated in all patients. Tumor assessments were made at baseline, before cycle 4, and every three cycles until disease progression occurred or 1 year of treatment was reached.
Statistical Methods
Sample size was estimated on the basis of historical experience of a 75% drop-out rate for pharmacokinetic assessments. Descriptive statistics were calculated for all pharmacokinetic parameters and efficacy variables. Tumor RRs and 95% CIs were calculated in a subset of patients with measurable disease. TTP was estimated from all patients by using the Kaplan-Meier method. RRs were assessed in all patients with measurable disease at baseline.
RESULTS
Patients
Patients were recruited from 12 centers in Spain, Canada, and the United Kingdom. Seventy-two women were eligible for enrollment and received at least one dose of study medication. Baseline demographic characteristics are listed in Table 1 .
Pharmacokinetics
A population pharmacokinetic model adequately described the pharmacokinetic analysis of 71 patients. 15 The median of primary parameter estimates for clearance was 0.231 L/d (fifth to 95th percentile range, 0.127 to 0.435 L/d), and terminal half-life was 18.8 days (fifth to 95th percentile range, 8.23 to 31.4 days). These were similar to the previous model developed with pharmacokinetic data obtained from conventional weekly or every-3-week regimens. 16 The trastuzumab serum concentration-time profiles are shown in comparison to the usual weekly and every-3-week regimens (Fig 1) and were simulated by using individual post hoc parameters for each patient who completed the scheduled regimen (n ϭ 60 to 67).
Median C min at the end of cycle 1 was 119 mg/L, which was higher than previously reported steady-state C min with conventional weekly and every-3-week regimens of 64.9 (fifth to 95th percentile range, 44.2 to 107 mg/L) and 47.3 mg/L (fifth to 95th percentile range, 19.6 to 51.2 mg/L), respectively (Table 2) . This demonstrated that patients achieved a higher C min within the first 3 weeks of treatment (by the end of cycle 1). Subsequent median C min levels at cycles 2 and 4 of the intensive loading regimen were 86.6 and 60.7 mg/L, respectively (Table 2), which showed that the higher C min was maintained for up to 12 weeks (at the end of cycle 4) compared with conventional regimens.
Safety Assessments
The median number of cycles of trastuzumab received per patient was 12 (range, 1 to 40), and the median cumulative dose per patient was 4,767 mg (range, 320 to 19,872 mg). Forty-six patients withdrew from study treatment because of disease progression, three because of AEs, two because of protocol violations, and one for administrative reasons. Twenty patients were still on treatment when the analysis was performed.
At least one AE was reported by 90% of patients (ie, 65 of 72 patients) during the study. The most commonly reported AEs were fatigue (31%), nausea (26%), chills (24%), headache (21%), diarrhea (19%), vomiting (17%), cough (15%), and pyrexia (14%). No new or unexpected AEs were observed. Grades 3 to 4 AEs were reported by 22% of patients (ie, 16 of 72 patients); dyspnea (n ϭ 3) and central line infection (n ϭ 2) were the most commonly observed grade 3 events (Table 3) . Only two grade 4 AEs were reported: cerebral ischemia and an increase in liver enzymes. These were considered unrelated to trastuzumab treatment. Treatment-related AEs were experienced by 44 patients, the majority being infusion-related symptoms occurring after the first dose of trastuzumab. Eight patients (11.1%) died as a result of disease progression during study treatment or within 28 days of the last dose of study treatment. Three patients withdrew from the study because of AEs (n ϭ 1 each because of left ventricular failure, amnesia, and hypoxia).
Absolute change in LVEF from baseline was assessed by echocardiography or MUGA scan at least every 12 weeks (Table 4 ). The median LVEF value at baseline was 63% (range, 50% to 79%). The majority of patients experienced an increase, no change, or an absolute decrease of less than 15 pp compared with baseline LVEF. An absolute LVEF decrease of Ն 15 pp was experienced by 8.2% of patients (ie, five of 61 patients), and only 1.6% of patients (ie, one of 61 patients) experienced an LVEF decrease to less than 40%. No patient had a decrease of Ն 15 pp and to less than 40% at any point during the study. LVEF decline was reported as an AE in only two patients: in one, trastuzumab was withdrawn for only one cycle until the LVEF value returned to normal, when trastuzumab treatment was resumed; the second patient withdrew from the study.
Most patients had no change from baseline in laboratory test parameter values. Only five patients experienced a grade 3 worsening from baseline in one or more laboratory parameter, and one patient had a grade 4 worsening in the levels of AST and ALT. These changes were considered related to the underlying disease.
ECOG PS was assessed throughout the study and was compared with baseline (median, 0; range, 0 to 2). Of 67 patients with paired ECOG PS overall, 74.6% had no change, 14.9% had a decrease, and 10.4% had improved PS.
Efficacy Assessments
RR was calculated in the 47 patients with measurable disease; the overall RR was 23.4% (complete response, 6.4%; partial response, 17.0%). Stable disease was reported in 27.7% of patients, and 42.6% had disease progression. Three patients (6.4%) were not evaluable for response, because postbaseline tumor assessments were not performed. Median TTP calculated in all 72 patients was 7.7 months (range, 0.3 to 25.5 months; Fig 2) . During the study, disease progression was experienced by 66.7% of patients (ie, 48 of 72 patients).
DISCUSSION
This single-arm, phase I/II study evaluated a novel, intensive loading regimen of trastuzumab for the treatment of patients with HER2-positive MBC. Abbreviation: AE, adverse event.
‫ء‬ All reported AEs are included, whether or not they were related to study treatment.
†One patient experienced two episodes of dyspnea. ‡One patient experienced dyspnea and bronchospasm associated with anaphylactic shock on receiving the first dose of trastuzumab.
§One patient experienced an increase in the levels of ALT and AST.
One patient experienced three grade 3 AEs: pleural effusion, pain in extremity, and lymphedema.
¶One patient experienced two episodes of diarrhea. 
‫ء‬
Includes data from additional examinations.
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Trastuzumab is currently licensed to be administered either weekly with a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg, or every 3 weeks with loading and maintenance doses of 8 mg/kg and 6 mg/kg, respectively.
10 These trastuzumab dosing regimens provide survival benefit for women with HER2-positive early breast cancer, as shown in four large, multicenter, open-label, randomized trials of adjuvant trastuzumab that had a total enrollment of 13,000 women. [17] [18] [19] In the HERA (HERceptin Adjuvant) trial, patients with HER2-positive early breast cancer who had previously received neoadjuvant or adjuvant chemotherapy, with or without radiation therapy, were randomly assigned to receive trastuzumab for 1 or 2 years (loading dose of 8 mg/kg followed by a maintenance dose of 6 mg/kg every 3 weeks) or no trastuzumab.
17,20 After a median follow-up of 2 years, a significant improvement in disease-free survival was observed with 1-year trastuzumab compared with observation alone, which demonstrated the good efficacy and tolerability profile of a higher loading dose of trastuzumab. 20 The 2-year data from the third arm are yet to reach maturity.
A phase II study that introduced a regimen of every-3-week trastuzumab (ie, loading dose of 8 mg/kg trastuzumab, then 6 mg/kg every 3 weeks) plus paclitaxel for women with HER2-positive MBC demonstrated similar pharmacokinetics to the weekly regimen.
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Mean trough concentrations, average exposure, and time to steadystate were similar with the every-3-week trastuzumab and the weekly trastuzumab regimen. The cumulative dose of trastuzumab was identical for both regimens. Trastuzumab plus paclitaxel was well tolerated, and clinical RRs were similar to those observed with the weekly regimen. Minimum trastuzumab serum concentrations for this every-3-week regimen were just less than the serum concentrations for the approved weekly regimen. The end-of-infusion values were approximately 25% higher after eight cycles of treatment.
The study described here has demonstrated that higher-thanestablished steady-state trastuzumab serum concentrations can be reached during cycle 1 of the every-3-week cycle. Achievement of a serum concentration at least equivalent to the established steady-state concentration in an early phase could be of clinical importance for patients, because this may lead to an early onset of tumor regression (particularly when given in combination with chemotherapy) or to disease-related symptom relief or improved PS.
The pharmacokinetic results are similar to those reported from a phase II study of trastuzumab monotherapy in 105 women with HER2-positive MBC. 22 In both of these every-3-week regimen studies, the C min trastuzumab serum concentrations were lower than in the approved weekly regimens, and the terminal half-life of trastuzumab was estimated to be 14.3 to 16.4 days. With the intensive loading regimen of trastuzumab, the mean C min (ie, 119 mg/L) in cycle 1 exceeded the steady-state concentrations normally recorded with either the weekly (ie, 66 mg/L) 9 or every-3-week (ie, 50.1 mg/L) trastuzumab regimen. 21 This had been anticipated when the study was designed, and it contributed to the decision to use an every-3-week regimen with a 6 mg/kg trastuzumab loading dose in cycle 1. The estimated median terminal half-life was 18.8 days, which is comparable to that of the earlier phase II study.
No new or unexpected AEs, laboratory abnormalities, or symptomatic CHF were reported in the study, and LVEF decreases of Ն 15 pp were fewer (ie, 8.2%) than previously reported (ie, 16.4%) in a study of patients with MBC who received every-3-week trastuzumab monotherapy. 22 However, the results reported here seem more in line with other published data, probably because of more careful patient selection and cardiac monitoring. In a pooled analysis of six trastuzumab trials, 2.0% to 15.0% of patients had an LVEF decrease of Ն 15 pp, depending on several risk factors.
23 Of those patients who had received previous anthracycline treatment, 10% experienced an LVEF decrease compared with 2% of those who had not received anthracycline treatment. Depending on the time between anthracycline and trastuzumab treatment, the LVEF decrease can differ between 15% and 6.7%. In a second, retrospective, pooled-data analysis from six trials (including this trial), low incidences of both symptomatic CHF (1.6%) and LVEF decrease leading to trastuzumab discontinuation (3.9%) were observed in 824 patients with MBC. 24 An LVEF decrease of Ն 15 pp was experienced by 13.2% of patients compared with 4.6% of those who did not receive trastuzumab. 24 Our study has demonstrated that an intensive loading regimen of trastuzumab does not result in an increased incidence of cardiotoxicity. This supports the previously published hypothesis that trastuzumab cardiotoxicity is not related to cumulative dose. 25 The overall RR of evaluable patients with measurable disease in this study was 23.4%. This compares with the RRs reported by two trials of weekly and every-3-week trastuzumab monotherapy in patients with HER2-positive MBC: 26% and 19% with first-line weekly trastuzumab 26 and first-line every-3-week trastuzumab, 22 respectively, and 15% with second-or third-line weekly trastuzumab. 6 The TTP in this trial (ie, 7.7 months) is longer than that reported for both the weekly regimen in the pivotal trial and the 3-weekly regimen (ie, 3.1 and 3.4 months, respectively). A third trial has presented TTPs of 3.5 and 3.8 months for patients receiving weekly trastuzumab 4 mg/kg or 2 mg/kg, respectively, 26 both of which are lower than that reported in the result of this study.
A recently published study comparing the efficacy of trastuzumab as monotherapy or in combination with chemotherapy reported a high RR of 31% and a TTP of 5.7 months for patients with recurrent breast cancer who received trastuzumab monotherapy.
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The median duration of response reported in this trial (ie, 7.9 months) was comparable with that reported for the every-3-week regimen (ie, 8.3 months).
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This intensive loading regimen achieved a higher-than-steadystate serum concentration of trastuzumab without compromising its efficacy and safety profile. This regimen could be of particular importance as neoadjuvant therapy, because patients would receive a high dose of trastuzumab early in their treatment, increasing potentially complete remissions.
In conclusion, this study has demonstrated that the intensive loading regimen of trastuzumab (6 mg/kg weekly for 3 weeks in cycle 1) followed by a maintenance dose of 6 mg/kg every 3 weeks is well tolerated in patients with MBC. Higher-than-steady-state serum concentrations were achieved during the first treatment cycle. The RRs and TTP achieved during the study indicate a promising efficacy profile for this intensive loading regimen. In number of citaƟons, JCO ranks second among 141 oncology journals and ranks 25th among all 6,598 scienƟfic journals surveyed. JCO arƟcles were cited more than 97,000 Ɵmes in 2008-a 20% increase over the previous year.
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